Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard-dose versus reduced-dose tenecteplase in acute ischemic stroke
IRCT20251213068308N1Phase 3Recruiting
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of tenecteplase in ischemic stroke (2 arms), sponsored by Zanjan University of Medical Sciences. Started Dec 2025; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on IRCT20251213068308N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251213068308N1.